Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2B, Randomized, Double-Blind, Comparator- & Placebo-Controlled, Dose Ranging Study to Evaluate Safety, Tolerability & Efficacy of 3 Dose Levels of Mitoglitazone in Type 2 Diabetic Patients

NCT01103414 is registered in ClinicalTrials.gov with Metabolic Solutions Development Company as lead sponsor.

NCT NCT01103414
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01103414 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2B, Randomized, Double-Blind, Comparator- & Placebo-Controlled, Dose Ranging Study to Evaluate Safety, Tolerability & Efficacy of 3 Dose Levels of Mitoglitazone in Type 2 Diabetic Patients
Lead sponsor
Metabolic Solutions Development Company
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2010
Completion date
December 31, 2011
Enrollment
356 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes